Drugs / Adeno-associated virus-CFTR vector
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00004533 | Aug 1999 → Aug 2002 | cystic fibrosis | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Adeno-associated virus-CFTR vector | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00004533 ↗ |
| Known as | AAV-CFTR | “adeno-associated virus-CFTR (AAV-CFTR) vector” NCT00004533 ↗ |
| Known as | rAAV-CFTR vector | “Doses of the rAAV-CFTR vector (tgAAVCF) ranging from 3 x 10(1) to 1 x 10(9) replication units (RU)” PMID 12885347 ↗ Jul 2003 |
| Known as | tgAAVCF | “Doses of the rAAV-CFTR vector (tgAAVCF) ranging from 3 x 10(1) to 1 x 10(9) replication units (RU)” PMID 12885347 ↗ Jul 2003 |
| Action | Restore | “stable correction of the CF defect in CF bronchial epithelial cells and stable expression of CFTR” PMID 12885347 ↗ Jul 2003 |
| Modality | Gene therapy (AAV / viral vector) | “Recombinant adeno-associated serotype 2-based vectors (rAAV2)” PMID 12885347 ↗ Jul 2003 |
| Target | CFTR | “rAAV2 vectors expressing the cystic fibrosis transmembrane conductance regulator (CFTR) gene” PMID 12885347 ↗ Jul 2003 |